C-RAD demonstrated its patient positioning solutions at the ASTRO. The CATALYST HD ™ system enjoyed large attention among the visitors. It was the first presentation of the system after its release to radiation oncologists in North America.
C-RAD demonstrated Catalyst HD™ in live shows on the main stage in the center of the booth. With the help of a model patient the clinical benefits were presented to the audience. The focus was to show the system for the setup of breast cancer patients as well as for stereotactic treatments. GEMini™ and Sentinel 4DCT™ were also presented as part of C-RADs radiation therapy workflow solutions.
The ASTRO's Annual Meeting is the largest radiation oncology scientific event worldwide. Every year it attracts more than 11,000 attendees. The ASTRO Meeting is attended mainly by radiation oncologists and medical physicists. The next ASTRO meeting will take place in San Antonio, Texas. C-RAD will install a CATALYST HD system in San Antonio during the fourth quarter this year.
“I am very satisfied with the results of the exhibition. The positive feedback from partners as well as clinical customers confirmed the large potential of the C-RAD products. With the help of our excellent sales team we will tap this potential and convert it into orders.” says Tim Thurn, CEO of C-RAD AB
About C-RAD
C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. All companies are located in Uppsala. Numbers of employees are currently 27 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD Sentinel TM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has invested in 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier. Erik Penser Bankaktiebolag is appointed as C-RAD’s Certified Adviser.
For more information on C-RAD, please visit www.c-rad.com .
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666947, E-mail investors@c-rad.com
The above information is price sensitive and must therefore be disclosed under the Securities Market Act (2077:528).
